Semaglutide, a weight loss drug Food and Drug Administration (FDA) approved in 2019, can be used to control appetite and reduce cravings for unhealthy food
180 Meanwhile, APOE4 could modify the behavior and function of activated microglia, contributing to increased A deposition, tau-associated neurodegeneration, enhanced inflammation, altered immune responses, and disrupted synaptic homeostasis
This risk is further compounded in MetALD patients, where the coexisting metabolic syndrome and alcohol consumption establish a uniquely high-risk population driven by synergistic insults (Ochoa-Allemant et al., 2025
10.1016/j.jalz.2015.08.043 76 EckmannJ.EckertS
2023;72(Supplement1):127OR
This medicine saved their lives